When Cancer Shifts into High Gear:

Castration Resistance Accelerates Prostate Cancer Kinetics - Jonnatan - The Prostate - Wiley Online Library

Understanding How Castration Resistance Changes Prostate Cancer Growth

Bottom Line Up Front (BLUF): New research shows that when prostate cancer develops resistance to hormone therapy (castration), it doesn't just continue at the same pace—it accelerates dramatically, doubling its growth rate. In one study, PSA doubling time nearly halved from 5.8 months before resistance to just 2.6 months after. This finding has important implications for when doctors should start hormone therapy in men with biochemical recurrence, especially those at higher risk of progression.

The Discovery: Cancer Gets Faster When It Becomes Resistant

For over 70 years, hormone therapy—androgen deprivation therapy, or ADT—has been the foundation of prostate cancer treatment. Yet clinicians have long noticed something troubling in their practices: once a cancer becomes castration-resistant (meaning it grows despite hormone therapy), it seems to progress much faster than before treatment started.

Until recently, nobody had proven this was actually happening. The observation could have been explained away: maybe the cancers that develop resistance are simply more aggressive to begin with, not faster because of the resistance itself.

A landmark 2024 study led by researcher Sheila Jonnatan at Johns Hopkins set out to answer this question by following individual patients before and after their cancer developed resistance. By comparing each person's cancer growth rate during biochemical recurrence (rising PSA before any visible metastases) to their growth rate after developing castration resistance, the researchers could isolate the true effect of resistance itself.

The Finding: Among 40 patients studied, 88% experienced a significant shortening of their PSA doubling time—meaning their cancer accelerated—once they developed castration resistance. On average, PSA doubling time fell from 5.8 months to just 2.6 months. That's a more than twofold increase in growth speed.

Why This Matters: The Biology Behind the Numbers

To understand why castration resistance revs up cancer growth, the researchers looked at tumor biopsies from 36 castration-resistant patients. They measured Ki-67, a protein that marks cells actively dividing and preparing to split.

The results were striking: the median Ki-67 level was 42%—meaning 42% of tumor cells were actively dividing. This is orders of magnitude higher than what's typically seen in primary, treatment-naive cancers, where Ki-67 levels are usually in the single digits.

Moreover, patients whose cancers were dividing fastest (highest Ki-67) had the shortest PSA doubling times—proving that the acceleration is driven at least partly by an increase in how fast cancer cells are reproducing.

What This Reveals About Cancer Biology: Castration resistance isn't just cancer "turning on" the hormone pathways again. Instead, the resistance mechanisms appear to create a fundamentally different, more aggressive cancer—one that reproduces faster and may be selected for cells with inherently higher proliferative capacity. This is an important distinction: reactivating hormone signaling alone does not fully explain the speed-up we see clinically.

The Timing Question: Should We Start Hormone Therapy Earlier?

This finding immediately raises a critical clinical question: if earlier hormone therapy means earlier development of faster-growing, more lethal cancer, would we actually be harming patients by starting treatment too soon?

The Johns Hopkins team explored this using mathematical modeling. They compared two scenarios for a typical high-risk patient with biochemical recurrence:

Scenario 1: Wait Until Metastases Appear, Then Start ADT

• 4 years of untreated biochemical recurrence (at 6-month PSA doubling time)
• 2 years of ADT controlling early metastatic disease
• 4 years of castration-resistant disease (at 2.5-month PSA doubling time) to death
• Estimated total survival: ~10 years

Scenario 2: Start ADT at Biochemical Recurrence

• Immediate ADT (90% tumor reduction)
• 2 years of controlled disease on ADT
• Development of castration resistance (at 2.5-month PSA doubling time) from that smaller tumor burden to death
• Estimated total survival: ~7.6 years

The model suggests that starting ADT early could cost patients 2.4 years of life compared to waiting—because when resistance does develop (which it eventually will), it develops from a residually smaller tumor, but then grows with the accelerated kinetics of castration resistance.

Important Caveat About This Model: This is a simplified mathematical exercise, not a clinical trial. It assumes that the depth and duration of ADT response are identical whether given early or late—which may not be true in reality. Modern newer-generation hormone agents (ARPIs like enzalutamide, apalutamide) have better response rates than the older data this model is based on. But the core principle—that when you start non-curative therapy matters—is real and worth understanding.

What Clinical Trials Actually Show (And Don't Show)

The Johns Hopkins model reveals something important: the debate over early versus late ADT has never been clearly settled by clinical trials. Here's where we stand:

The Evidence Base: A comprehensive 2025 systematic review examined 26 studies on this question. The verdict? Early ADT may delay progression, but its impact on overall survival remains unclear. Most large observational studies found no survival difference between immediate and delayed ADT for biochemical recurrence. The one prospective trial (TOAD) that showed a benefit to early ADT was underpowered and enrolled only 261 of its planned 750 patients.

However—and this is critical—a subgroup analysis did find a survival benefit for early ADT in men with very rapid PSA doubling time (less than 9 months). This suggests that the decision to treat early should be risk-stratified: it's not one-size-fits-all.

Current Guidelines (EAU, AUA, NCCN):

• For high-risk biochemical recurrence (PSADT ≤ 9 months), consider early treatment with enzalutamide (with or without ADT)
• For lower-risk BCR (PSADT > 12 months), surveillance is reasonable, even for years
• For intermediate-risk patients, decision-making should be individualized based on age, comorbidities, and patient preferences regarding side effects

The Newer Treatment Landscape: ARPIs Change the Equation

One crucial limitation of the Johns Hopkins study and the mathematical model is that they were based on older treatment paradigms. Most of the patients in the cohort were treated decades ago, when the only option was standard ADT (LHRH agonists), possibly combined with old-generation antiandrogens.

Today's landscape is different. Second-generation androgen receptor pathway inhibitors (ARPIs)—like enzalutamide (Xtandi), apalutamide (ARylone), and darolutamide (Nubeqa)—are far more potent than the drugs available when these patients were treated.

Two recent trials show the impact:

• EMBARK trial: Showed that apalutamide plus ADT delayed metastasis significantly better than ADT alone in men with high-risk BCR
• PRESTO trial (2024): Found that 1 year of intensified ADT (adding an ARPI to standard ADT) prolonged PSA progression-free survival by 4–6 months in high-risk BCR patients compared to ADT alone

These results suggest that starting treatment earlier with modern agents might change the calculus compared to older ADT-only approaches. However, this benefit must still be weighed against ADT's side effects—hot flashes, sexual dysfunction, bone loss, cardiovascular risk—which can significantly impact quality of life, especially over years of continuous therapy.

A Critical Clinical Practice Gap: Doctors Often Miss PSADT

In recent 2025 data presented at the American Society of Clinical Oncology symposium, researchers found a troubling problem: treating physicians are often unaware of their patients' PSA doubling time at biochemical recurrence.

In a chart review of 284 BCR patients, nearly two-thirds of treating physicians either didn't know or failed to document the PSADT. When they did know it, 88% of the time they overestimated it—meaning they underestimated their patient's cancer aggressiveness and missed the window for guideline-recommended treatment escalation.

The bottom line: if you have a BCR diagnosis, make sure your doctor has accurately calculated your PSA doubling time. It's one of the strongest predictors of your cancer's behavior and should drive treatment decisions.

How to Calculate Your PSA Doubling Time: You need at least three PSA values at roughly 3-month intervals. A urologist or oncologist can do this, but you can also ask: What is my PSADT? Get the number in writing. If it's less than 9 months, you likely have high-risk disease requiring closer monitoring and treatment discussion. If it's greater than 12 months, you have lower-risk disease and surveillance may be appropriate.

What Research Is Emerging: The Ki-67 Question

The Johns Hopkins data pointing to increased cell proliferation (Ki-67) as a driver of castration-resistant growth raises questions for future research:

• Could measuring Ki-67 at the time of castration resistance help identify which patients will progress fastest and need most aggressive treatment?
• Are there therapies that slow castration-resistant cancer by directly targeting its increased proliferation (chemotherapy, cell-cycle inhibitors, etc.)?
• Does giving certain treatments earlier, when the tumor burden is smaller, allow better control even if resistance eventually develops?

These remain open questions, with multiple clinical trials underway to answer them.

Bottom Line for Patients

If you're living with biochemical recurrence, here's what this research means for you:

1. Know Your PSADT. This number matters enormously. Make sure it's been calculated accurately and that your doctor can discuss what it means for your risk level.
2. If You're High-Risk (PSADT ≤ 9 months), have a focused conversation with your oncologist or urologist about whether to start hormone therapy now or use advanced imaging (PSMA PET) to look for small metastases. The evidence suggests that delaying treatment in high-risk patients is risky.
3. If You're Lower-Risk (PSADT > 12 months), you have more time. Surveillance every 3–4 months is reasonable. You can delay the side effects of hormone therapy while your cancer progresses slowly.
4. Understand the Cost-Benefit. Hormone therapy does extend life and delay progression, but it carries side effects. Discuss with your doctor: Am I someone for whom early treatment's benefits clearly outweigh the harms? The answer depends on your age, health, comorbidities, and personal values.
5. Newer Is Better—But Not Magic. If you do start treatment, modern ARPIs are more effective than the older drugs. But they still eventually face resistance, and resistance accelerates growth. Long-term strategies—including chemotherapy, targeted isotope therapy (Lu-177, Ac-225), and clinical trials—will likely play a role in your journey.

Key Takeaway

The Johns Hopkins research reveals an uncomfortable truth: when prostate cancer develops hormone resistance, it becomes not just resistant but faster. This finding reframes how we think about the timing of treatment. It's not simply "treat early to prevent metastases." It's a more complex calculation: early treatment might delay metastasis but could accelerate the lethal phase of disease. The answer for any given patient depends on risk stratification, life expectancy, and shared decision-making with your medical team.

The good news is that guideline-based risk stratification using PSADT and other factors now allows for much more individualized treatment planning than in the past. And newer drugs are more effective than what was available even a few years ago. The key is being informed, knowing your own cancer's behavior metrics, and engaging actively with your care team.

---

Sources and Further Reading

This article synthesizes findings from the following peer-reviewed research, clinical guidelines, and recent presentations:

Primary Research Article:
Jonnatan, S. (2024). "Castration Resistance Accelerates Prostate Cancer Kinetics." Wiley Online Library. [Accessed from original Wiley publication in Wiley journals archives]
This landmark study quantified the acceleration of PSA doubling time following development of castration resistance in 40 men with BCR.

Recent Systematic Reviews and Clinical Guidance:
Karim, M.U., Tisseverasinghe, S., Cartes, R., Martinez, C., Bahoric, B., & Niazi, T. (2025). "Early Versus Delayed Androgen Deprivation Therapy for Biochemical Recurrence After Local Curative Treatment in Non-Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review of the Literature." Cancers, 17(2), 215. https://doi.org/10.3390/cancers17020215
Comprehensive review of 26 studies examining early vs. delayed ADT initiation for BCR, published January 2025.

Treatment Timing in High-Risk BCR:
American Urological Association (AUA). "Advanced Prostate Cancer: AUA/SUO Guideline." https://www.auanet.org/guidelines-and-quality/guidelines/advanced-prostate-cancer
Official AUA guidance on timing of systemic therapy, salvage approaches, and risk stratification for BCR and CRPC.

nmCRPC Risk Stratification and PSADT Cutoffs:
Ogasawara, T., Hashimoto, K., Shindo, T., et al. (2025). "Optimal Timing of Treatment Initiation in Non-Metastatic Castration-Resistant Prostate Cancer Based on PSA Level and Doubling Time for Prognostic Benefit." Cancers, 17(22), 3641. https://doi.org/10.3390/cancers17223641
November 2025 study of 450 nmCRPC patients defining PSADT stability and optimal treatment timing.

Japanese Multi-Center PSADT Cutoff Analysis:
Sakamoto, S., Sato, K., Kimura, T., et al. (2024). "PSA Doubling Time 4.65 Months as an Optimal Cut-off of Japanese Nonmetastatic Castration-Resistant Prostate Cancer." Scientific Reports, 14, 15307. https://doi.org/10.1038/s41598-024-65969-3
Multi-center study of 450 nmCRPC patients identifying optimal PSADT prognostic cutoffs using survival tree analysis.

Clinician Awareness Gap in BCR Management:
Morgans, A., Touya, M., El-Chaar, N., et al. (2025). "Impact of Physicians' Awareness of Prostate-Specific Antigen Doubling Time (PSADT) on Treatment (Tx) Decisions in High-Risk (HR) Biochemically Recurrent (BCR) Prostate Cancer (PC)." Poster 354, ASCO Genitourinary Cancers Symposium, February 13–15, 2025, San Francisco, California.
Chart review of 284 BCR patients showing that 64% of treating physicians either don't know or fail to document PSADT.

Ki-67 Proliferation as Biomarker:
Jonnatan, S., et al. (2024). Correlation analysis of CR-PSADT with Ki-67 index in 36 metastatic CRPC tumor biopsies from NCT03554317 trial patients. [Referenced within primary Jonnatan study above]
Found significant negative correlation between CR-PSADT and Ki-67 index (r = −0.48, p = 0.027), implicating increased proliferation in castration-resistant acceleration.

PSADT Thresholds and Risk Stratification:
Freedland, S.J., et al. (2017). "Thresholds for Prostate-Specific Antigen Doubling Time in Men with Non-Metastatic Castration-Resistant Prostate Cancer." The Journal of Urology, 197(5), 1446–1453. https://doi.org/10.1016/j.juro.2016.11.099
Veterans Affairs multi-center study identifying PSADT thresholds (<3, 3–8.9, 9–14.9, ≥15 months) predictive of metastasis and survival in 441 nmCRPC patients.

PSADT Stability Over Time and Tumor Progression:
Whitney, C.A., Howard, L.E., Freedland, S.J., et al. (2019). "Impact of Age, Comorbidity, and PSA Doubling Time on Long-Term Competing Risks for Mortality Among Men with Non-Metastatic Castration-Resistant Prostate Cancer." Prostate Cancer and Prostatic Diseases, 22, 252–260. https://doi.org/10.1038/s41391-019-0127-4
Analysis supporting PSADT as stable, independent predictor of metastasis-free and overall survival.

High-Risk BCR Definition and EAU Guidelines:
Van den Broeck, T., van den Bergh, R.C.N., Arfi, N., et al. (2019). "Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review." European Urology, 75(6), 967–987. https://doi.org/10.1016/j.eururo.2019.01.047
Foundational systematic review underpinning EAU high-risk BCR definition (PSADT ≤9 months, high Gleason grade).

Recent Clinical Trial Evidence (PRESTO):
Aggarwal, R., Heller, G., Hillman, D.W., et al. (2024). "PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients with High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19)." Journal of Clinical Oncology, 42(10), 1114–1123. https://doi.org/10.1200/JCO.23.02007
2024 phase III trial showing 1 year of enzalutamide + ADT vs. ADT alone prolonged PSA-PFS by 4–6 months in high-risk BCR.

Economics and Healthcare Burden of Rapid PSADT:
Belliere, J., Moul, J.W., Banez, L.L., et al. (2023). "Survival and Economic Impact of Rapid Prostate-Specific Antigen Doubling Time in Patients with Nonmetastatic Castration-Resistant Prostate Cancer." European Urology Oncology, 6(1), 88–96. https://doi.org/10.1016/j.euo.2023.01.007
Veterans Health Administration study of 2,800 nmCRPC patients showing risk of metastasis and mortality increases stepwise with decreasing PSADT; PSADT ≤2 months carries 12.3-fold increased mortality risk.

Risk-Stratified Management Overview:
Rosinha, A., Rabaça, C., Calais, F., et al. (2024). "Improving the Identification of High-Risk Non-Metastatic Castration-Resistant Prostate Cancer Patients in Clinical Practice." Frontiers in Oncology, 13, 1266369. https://doi.org/10.3389/fonc.2023.1266369
Comprehensive expert review on standardization of nmCRPC identification and risk stratification using PSADT, PSA velocity, and imaging.

CRPC as Intermediate Endpoint in BCR:
Xie, W., Ravi, P., Graff, R.E., et al. (2022). "Is Time to Castration-Resistant Prostate Cancer a Potential Intermediate End-Point for Time to Metastasis Among Men Initiating Androgen Deprivation Therapy for Non-Metastatic Prostate Cancer with Rapid PSA Doubling Time (<9 Months)?" Prostate Cancer and Prostatic Diseases, 25, 547–554. https://doi.org/10.1038/s41391-022-00585-8
Analysis of 210 BCR patients with PSADT <9 months showing strong correlation (Kendall's Tau = 0.867) between CRPC-free survival and metastasis-free survival.

This article is intended for educational purposes and does not replace consultation with your medical oncologist or urologist. Individual treatment decisions should be made in collaboration with your healthcare team.